If you’re still managing cholesterol the same way as before, you may be undertreating your patients.
The 2026 dyslipidemia (cholesterol) guidelines introduce major updates that shift how we approach LDL targets, combination therapy, and non-statin treatments.
In this video, I break down the most practical, practice-changing updates so you can apply them immediately on rounds.
???? What You’ll Learn in This Video:
Why LDL targets are now even lower (less than 55)
When to start combination therapy early (statin + ezetimibe)
Why PCSK9 inhibitors are no longer last-line
The importance of checking Lipoprotein(a) [Lp(a)] at least once
New treatment options like inclisiran and bempedoic acid
The shift toward faster and more aggressive lipid lowering
⚡ Key Takeaway:
???? Treat earlier
???? Treat faster
???? Treat more aggressively
If your patient has ASCVD and their LDL is still elevated—waiting is no longer the standard of care.
????⚕️ Who This Video Is For:
Physicians (Hospitalists, IM, Cardiology)
Medical students & residents
Nurse practitioners & PAs
Anyone interested in evidence-based cardiovascular prevention
???? About the Channel:
SmartHospitalist– Bridging Health, Medicine & Culture
I break down practice-changing medical updates into simple, actionable content for busy healthcare professionals.
???? If You Found This Helpful:
Like ????
Subscribe ????
Share with a colleague
???? Let’s Discuss:
What’s the biggest change this guideline will make in your practice?
KEYWORDS
2026 cholesterol guidelines, dyslipidemia guidelines 2026, LDL targets 2026, PCSK9 inhibitors explained, lipoprotein a screening, statin therapy updates, ezetimibe combination therapy, inclisiran, bempedoic acid, cardiovascular risk management
#Cholesterol #LDL #Cardiology #InternalMedicine #MedEd #Dyslipidemia #PCSK9 #MedicalEducation #Healthcare #smarthospitalist
The 2026 dyslipidemia (cholesterol) guidelines introduce major updates that shift how we approach LDL targets, combination therapy, and non-statin treatments.
In this video, I break down the most practical, practice-changing updates so you can apply them immediately on rounds.
???? What You’ll Learn in This Video:
Why LDL targets are now even lower (less than 55)
When to start combination therapy early (statin + ezetimibe)
Why PCSK9 inhibitors are no longer last-line
The importance of checking Lipoprotein(a) [Lp(a)] at least once
New treatment options like inclisiran and bempedoic acid
The shift toward faster and more aggressive lipid lowering
⚡ Key Takeaway:
???? Treat earlier
???? Treat faster
???? Treat more aggressively
If your patient has ASCVD and their LDL is still elevated—waiting is no longer the standard of care.
????⚕️ Who This Video Is For:
Physicians (Hospitalists, IM, Cardiology)
Medical students & residents
Nurse practitioners & PAs
Anyone interested in evidence-based cardiovascular prevention
???? About the Channel:
SmartHospitalist– Bridging Health, Medicine & Culture
I break down practice-changing medical updates into simple, actionable content for busy healthcare professionals.
???? If You Found This Helpful:
Like ????
Subscribe ????
Share with a colleague
???? Let’s Discuss:
What’s the biggest change this guideline will make in your practice?
KEYWORDS
2026 cholesterol guidelines, dyslipidemia guidelines 2026, LDL targets 2026, PCSK9 inhibitors explained, lipoprotein a screening, statin therapy updates, ezetimibe combination therapy, inclisiran, bempedoic acid, cardiovascular risk management
#Cholesterol #LDL #Cardiology #InternalMedicine #MedEd #Dyslipidemia #PCSK9 #MedicalEducation #Healthcare #smarthospitalist
- Categoria
- Cardiology
Commenta per primo questo video.









